|本期目录/Table of Contents|

CAR-T细胞治疗多发性骨髓瘤的研究进展

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:
2019年20期
页码:
3729-3732
栏目:
综述
出版日期:
2019-09-08

文章信息/Info

Title:
Advances in the treatment of multiple myeloma by CAR-T cells
作者:
李逸豪;?王建勋
北京中医药大学生命科学学院,北京 102400
Author(s):
Li Yihao;?Wang Jianxun
School of Life Sciences,Beijing University of Chinese Medicine,Beijing 102400,China.
关键词:
CAR-T细胞疗法;?多发性骨髓瘤;?嵌合抗原受体;?不良反应
Keywords:
CAR-T cell immunotherapy;?multiple myeloma;?chimeric antigen receptor;?adverse reactions
分类号:
R733.3
DOI:
10.3969/j.issn.1672-4992.2019.20.042
文献标识码:
A
qq自动领红包软件:
多发性骨髓瘤(MM)是一种源于骨髓浆细胞的恶性肿瘤,截止目前尚无有效的治愈手段。嵌合抗原受体(CAR)-T细胞疗法是一种具有广阔研究前景的MM治疗方法。其设计理念是通过对部分基因序列进行特异性的改造,使CAR特异性地影响靶向肿瘤细胞的抗原,受体与抗原相结合以激活T细胞杀死肿瘤细胞。本文主要阐述CAR-T细胞疗法的设计过程、研究进展及现阶段所面临的缺陷。
Abstract:
Multiple myeloma (MM) is a malignant tumor derived from bone marrow plasma cells,and there is currently no effective cure.Chimeric antigen receptor (CAR)-T cell immountherapy is a promising MM therapy.Its design concept is to specifically modify part of the gene sequence so that CAR can specifically affect antigens targeting tumor cells,and the receptor can be combined with antigens to activate T cells to kill tumor cells.This article mainly describes the design process,research progress and defects faced by CAR-T cell immunotherapy.

参考文献/References

[1]Chinese Hematology Branch of Chinese Medical Doctors Association,Hematology Branch of Chinese Medical Association,Multiple Myeloma Professional Committee of Chinese Medical Doctors Association.Chinese multiple myeloma diagnosis and treatment guidelines (revised in 2017)[J].Chinese Journal of Internal Medicine,2017,56(11):866-870.[中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2017年修订)[J].中华内科杂志,2017,56(11):866-870.]
[2]Cornell RF,Kassim AA.Evolving paradigms in the treatment of relapsed/refractory multiple myeloma:Increased options and increased complexity[J].Bone Marrow Transplant,2016,51(4):479-491.
[3]Laubach J,Garderet L,Mahindra A,et al.Management of relapsed multiple myeloma:Recommendations of the International Myeloma Working Group[J].Leukemia,2016,30(5):1005-1017.
[4]Riddell SR,Sommermeyer D,Berger C,et al.Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition[J].Cancer Journal,2014,20(2):141-144.
[5]Li F,Zhang T,Cao L,et al.Chimeric antigen receptor T cell based immunotherapy for cancer[J].Current Stem Cell Research & Therapy,2018,13(5):327-335.
[6]Anurathapan U,Chan RC,Hindi HF,et al.Kinetics of tumor destruction by chimeric antigen receptor-modified T cells[J].Molecular Therapy,2014,22(3):623-633.
[7]Gross G,Waks T,Eshhar Z.Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with anti-body-type specificity[J].Proc Natl Acad Sci USA,1989,86 (24):10024-10028.
[8]Park TS,Rosenberg SA,Morgan RA.Treating cancer with genetically engineered T cells[J].Trends in Biotechnology,2011,29(11):550-557.
[9]Carpenito C,Milone MC,Hassan R,et al.Control of large,established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains[J].Proceedings of the National Academy of Sciences of the United States of America,2009,106(9):3360-3365.
[10]Zhao Z,Condomines M,Vall der Stegen SJ,et al.Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells[J].Cancer Cell,2015,28(4):415-428.
[11]Srivastava S,Riddell SR.Engineering CAR-T cells:Design concepts[J].Trends Immunol,2015,36(8):494-502.
[12]Cheng Z,Liu J,Zhong JF,et al.Engineering CAR-T cells[J].Biomarker Research,2017,5(1):22.
[13]Pang Y,Hou X,Yang C,et al.Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy[J].Molecular Cancer,2018,17(1):91.
[14]Ramos CA,Dotti G.Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy[J].Expert Opinion on Biological Therapy,2011,11(7):855-873.
[15]Garfall AL,Stadtmauer EA,Maus MV,et al.Pilot study of anti-CD19 chimeric antigen receptor T cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple myeloma[J].Blood,2016(128):974.
[16]Muoz P,Pavón EJ,Salmerón J,et al.CD38 signaling in T cells is initiated within a subset of membrane rafts containing Lck and the CD3-ζ subunit of the T cell antigen receptor[J].Journal of Biological Chemistry,2003,278(50):50791-50802.
[17]Kawano Y,Fujiwara S,Wada N,et al.Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide[J].Int J Oncol,2012,41(3):876-884.
[18]Guo B,Chen M,Han Q,et al.CD138-directed adoptive immunotherapy of chimeric antigen receptor(CAR)-modified T cells for multiple myeloma[J].J Cell Immunother,2016,2(1):28-35.
[19]McEarchern JA,Smith LM,McDonagh CF,et al.Preclinical characterization of SGN-70,a humanized antibody directed against CD70[J].Clinical Cancer Research,2008,14(23):7763-7772.
[20]Ramos CA,Savoldo B,Torrano V,et al.Clinical responses with T lymphocytes targeting malignancy-associated κ light chains[J].Journal of Clinical Investigation,2016,126(7):2588-2596.
[21]Ali SA,Shi V,Maric I,et al.T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma[J].Blood,2016,128(13):1688-1700.
[22]CAR T-cell therapy impresses in multiple myeloma[R/OL].Cancer Discovery,2018,8(2):OF2.http://cancerdiscovery.aacrjournals.org/content/8/2/OF2.DOI:10.1158/2159-8290.CD-NB2017-181.
[23]Carpenter RO,Evbuomwan MO,Pittaluga S,et al.B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma[J].Clinical Cancer Research,2013,19(8):2048-2060.
[24]Cannons JL,Tangye SG,Schwartzberg PL.SLAM family receptors and SAP adaptors in immunity[J].Annual Review of Immunology,2011,29(1):665-705.
[25]Wang X,Walter M,Urak R,et al.Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma[J].Clinical Cancer Research,2018,24(1):106-119.
[26]Burstein DS,Maude S,Grupp S,et al.Cardiac profile of chimeric antigen receptor T cell therapy in children:A single-institution experience[J].Biology of Blood and Marrow Transplantation,2018,24(8):1590-1595.
[27]June CH,O' Connor RS,Kawalekar OU,et al.CAR T cell immunotherapy for human cancer[J].Science,2018,359(6382):1361-1365.

备注/Memo

备注/Memo:
教育部双一流引导专项师资队伍建设项目(编号:1000061020014)
更新日期/Last Update: 1900-01-01